Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK-PeriMF: Gecacitinib in Peri-Transplant Period for Myeloid Neoplasms and Myelofibrosis
NCT07883382Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of jaktinib in myeloid neoplasms, myelofibrosis (MF), sponsored by Ruijin Hospital. Started Oct 2026; status: recruiting.
02
Drugs
jaktinib
03
Conditions
myeloid neoplasmsmyelofibrosis (MF)
Beyond the preview
Go deeper on NCT07883382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07883382.